These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 25920521)

  • 1. Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A.
    Sarkar S; van Gelder M; Noort W; Xu Y; Rouschop KM; Groen R; Schouten HC; Tilanus MG; Germeraad WT; Martens AC; Bos GM; Wieten L
    Cancer Immunol Immunother; 2015 Aug; 64(8):951-63. PubMed ID: 25920521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of NKG2A-LIR1- natural killer cells in HLA-matched, killer cell immunoglobulin-like receptors/HLA-ligand mismatched patients following hematopoietic cell transplantation.
    Rathmann S; Glatzel S; Schönberg K; Uhrberg M; Follo M; Schulz-Huotari C; Kaymer M; Veelken H; Finke J; Fisch P
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):469-81. PubMed ID: 20044012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans.
    Bigley AB; Rezvani K; Shah N; Sekine T; Balneger N; Pistillo M; Agha N; Kunz H; O'Connor DP; Bollard CM; Simpson RJ
    Clin Exp Immunol; 2016 Aug; 185(2):239-51. PubMed ID: 26940026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling
    Mahaweni NM; Ehlers FAI; Bos GMJ; Wieten L
    Front Immunol; 2018; 9():2848. PubMed ID: 30564241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NKG2A Expression Is Not
    Mahaweni NM; Ehlers FAI; Sarkar S; Janssen JWH; Tilanus MGJ; Bos GMJ; Wieten L
    Front Immunol; 2018; 9():1415. PubMed ID: 29988376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors.
    Della Chiesa M; Vitale M; Carlomagno S; Ferlazzo G; Moretta L; Moretta A
    Eur J Immunol; 2003 Jun; 33(6):1657-66. PubMed ID: 12778484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma.
    Tognarelli S; Wirsching S; von Metzler I; Rais B; Jacobs B; Serve H; Bader P; Ullrich E
    Front Immunol; 2018; 9():2743. PubMed ID: 30542346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells.
    Sarkar S; Germeraad WT; Rouschop KM; Steeghs EM; van Gelder M; Bos GM; Wieten L
    PLoS One; 2013; 8(5):e64835. PubMed ID: 23724099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.
    Kamiya T; Seow SV; Wong D; Robinson M; Campana D
    J Clin Invest; 2019 May; 129(5):2094-2106. PubMed ID: 30860984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.
    Braud VM; Allan DS; O'Callaghan CA; Söderström K; D'Andrea A; Ogg GS; Lazetic S; Young NT; Bell JI; Phillips JH; Lanier LL; McMichael AJ
    Nature; 1998 Feb; 391(6669):795-9. PubMed ID: 9486650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells.
    Ruggeri L; Urbani E; André P; Mancusi A; Tosti A; Topini F; Bléry M; Animobono L; Romagné F; Wagtmann N; Velardi A
    Haematologica; 2016 May; 101(5):626-33. PubMed ID: 26721894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
    Oei VYS; Siernicka M; Graczyk-Jarzynka A; Hoel HJ; Yang W; Palacios D; Almåsbak H; Bajor M; Clement D; Brandt L; Önfelt B; Goodridge J; Winiarska M; Zagozdzon R; Olweus J; Kyte JA; Malmberg KJ
    Cancer Immunol Res; 2018 Apr; 6(4):467-480. PubMed ID: 29459477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus: an unlikely ally in the fight against blood cancers?
    Bigley AB; Baker FL; Simpson RJ
    Clin Exp Immunol; 2018 Sep; 193(3):265-274. PubMed ID: 29737525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-E regulates NKG2C+ natural killer cell function through presentation of a restricted peptide repertoire.
    Lauterbach N; Wieten L; Popeijus HE; Voorter CE; Tilanus MG
    Hum Immunol; 2015 Aug; 76(8):578-86. PubMed ID: 26382247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selenite induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/NKG2A-positive NK cells.
    Enqvist M; Nilsonne G; Hammarfjord O; Wallin RP; Björkström NK; Björnstedt M; Hjerpe A; Ljunggren HG; Dobra K; Malmberg KJ; Carlsten M
    J Immunol; 2011 Oct; 187(7):3546-54. PubMed ID: 21890659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I.
    Wu X; Shao Y; Tao Y; Ai G; Wei R; Meng X; Hou J; Han Y; Zhan F; Zheng J; Shi J
    Biochem Biophys Res Commun; 2011 Nov; 415(1):187-92. PubMed ID: 22033416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial break in tolerance of NKG2A
    Rathmann S; Keck C; Kreutz C; Weit N; Müller M; Timmer J; Glatzel S; Follo M; Malkovsky M; Werner M; Handgretinger R; Finke J; Fisch P
    Bone Marrow Transplant; 2017 Aug; 52(8):1144-1155. PubMed ID: 28481352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice.
    Li F; Wei H; Wei H; Gao Y; Xu L; Yin W; Sun R; Tian Z
    Gastroenterology; 2013 Feb; 144(2):392-401. PubMed ID: 23103614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.
    Swift BE; Williams BA; Kosaka Y; Wang XH; Medin JA; Viswanathan S; Martinez-Lopez J; Keating A
    Haematologica; 2012 Jul; 97(7):1020-8. PubMed ID: 22271890
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Liu LL; Béziat V; Oei VYS; Pfefferle A; Schaffer M; Lehmann S; Hellström-Lindberg E; Söderhäll S; Heyman M; Grandér D; Malmberg KJ
    Cancer Immunol Res; 2017 Aug; 5(8):654-665. PubMed ID: 28637877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.